PT-141 / Bremelanotide
Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for PT-141 / Bremelanotide.
May increase sexual desire in premenopausal women with HSDD
Can improve sexual arousal and responsivity in some patients
Rapid onset of action (commonly within 30–60 minutes)
On‑demand, single‑dose subcutaneous administration
Acts centrally via melanocortin (MC4R) pathways
Non‑hormonal mechanism—alternative to estrogen/testosterone
Shown efficacy in randomized controlled trials
May reduce distress associated with low sexual desire
Does not require daily dosing for many patients
Option when hormonal therapy is contraindicated or undesired
This peptide's combination-safety and interaction data below always stays visible, regardless of membership.
Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.
Discussions
Community discussions are coming soon.